Myrrh

drug
On this page

Also known as Bola resinCommiphora molmol resinCommiphora myrrha gum resinCommiphora myrrha resinCommon myrrhFEMA NO. 2765Hirabol myrrhMo yaoMolmolMoyao (commiphora molmol)Moyao (commiphora myrrha)Myrrh (commiphora molmol)Myrrh (commiphora myrrha)Myrrh (gum) (commiphora molmol)MyrrhaMyrrha (commiphora molmol)Myrrha (commiphora myrrha)Somalian myrrh

Summary

Myrrh (CHEMBL2109203) is a phase-3 clinical-stage unknown.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Clinical trials: 2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2109203
NameMyrrh
TypeUnknown
Max phase3

Also known as: Bola resin, Commiphora molmol resin, Commiphora myrrha gum resin, Commiphora myrrha resin, Common myrrh, FEMA NO. 2765, Hirabol myrrh, Mo yao, Molmol, Moyao (commiphora molmol), Moyao (commiphora myrrha), Myrrh

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

PhaseTrials
PHASE31
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01529710PHASE3COMPLETEDSafety and Efficacy of Mirazid for Schistosomiasis Treatment
NCT04723732Not specifiedCOMPLETEDAntiplaque, Antigingivitis and Anti-inflammatory Effects of Myrrh Mouthwash

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.